What kind of drug is Entrectinib

1. Product Ingredients

Entrectinib is a small molecule tyrosine kinase inhibitor with the chemical name N-(4-(3-(4-(6-(2-fluoro-4-(trifluoromethyl)phenyl)thiazol-2-yl)thiazol-2-yl)phenyl)thiazol-2-yl)phenyl)-4-(4-fluorophenyl)thiazole-2-amine. Its molecular formula is C21H21F3N4S3 and its molecular weight is 468.59.

2. Efficacy

Entrectinib interferes with the growth and spread of cancer cells by inhibiting certain types of tyrosine kinases, particularly ROS1, NTRK1, NTRK2, and NTRK3. This drug has a strong inhibitory effect on cancer cells that carry these gene fusions or mutations, so it is highly effective in treating these types of cancer.

3. How to use

Entrectinib is usually given as an oral tablet. The usual dose is 100 mg twice daily. The specific dose and regimen should be adjusted according to the patient's specific condition and the tolerability of the drug. Follow your doctor's advice when using it.

4. R&D history

Entrectinib was developed by F. Hoffmann-La Roche developed and first received US Food and Drug Administration (FDA) approval for the treatment of ROS1 fusion-positive non-small cell lung cancer (NSCLC) and NTRK fusion-positive solid tumors in 2019. It is the first approved NTRK inhibitor and is also used for the treatment of ROS1-positive cancers, marking a further advance in targeted therapy in cancer treatment.

5. Drug regime

Entrectinib reduces the growth and spread of cancer cells by targeting and inhibiting ROS1, NTRK1, NTRK2, and NTRK3 tyrosine kinases, blocking the signaling of these receptors. Specifically, it is able to interfere with these receptor-mediated cell proliferation and survival signals, especially effective for cancer cells with ROS1 or NTRK gene fusions.

6. Summary of medicines

Entrectinib is a targeted drug targeting ROS1 and NTRK gene fusions for the treatment of related types of cancer. It exerts anti-cancer effects by inhibiting related tyrosine kinases, interfering with the growth and spread of cancer cells. Entrectinib has shown promising results in the treatment of cancers with certain specific gene mutations or fusions.